DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ndlc5t/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024" report to their offering.
The global Acute Myeloid Leukemia market will reach a value of $932 million in 2024 at a CAGR of 10.5%.
Key Topics Covered:
- Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized AML therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (including, young patients, elderly patients, refractory/relapsed patients and FLT3 mutated patients), forecast from 2014 to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AML therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
Benefits of this Report:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AML therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Companies Mentioned:
- Actinium pharmaceuticals
- Agios pharmaceuticals
- Astellas Pharmaceuticals
- Ambit Biosciences
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celator Pharmaceuticals
- Celgene
- CTI BioPharma
- Cyclacel
- Daiichi Sankyo
- Eisai
- Epizyme
- Janssen-Cilag
- Novartis
- Merus
- MEI Pharma
- Otsuka Pharmaceuticals
- Pfizer
- Sanofi
- Seattle Genetics
- Stemline Therapeutics
- Sunesis
- Sumitomo Dainippon Pharma
-
Synta Pharmaceuticals
Report Structure:
1.1 List of Tables
1.2 List of Figures
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
7 Unmet Needs Assessment and Opportunity Analysis
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Appendix
For more information visit http://www.researchandmarkets.com/research/ndlc5t/opportunityanalyze
